Compositions and methods for treating type 2 diabetes and its sequelae by intravenous or subcutaneous administration of formulations of synthesized curcumin (diferuloylmethane) and concomitantly one or more anti-diabetic agents to human subjects are disclosed herein. The composition of the present invention may be used to: (i) treat patients with diabetes in advanced stages with evidence of any or all encephalopathy retinopathy nephropathy pancreatitis or neoplasias; (ii) treat patients with dia...

Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g. aspartate or glutamate) metformin and polyunsaturated fatty acids such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes diabetes with concomitant dyslipidemia (e.g. high triglycerides) and diabetes exacerbated cardiovascular complications such as cardiac arrhythmia cardiac ischemia myocardial infarction cardiomyopathy a...

Provided herein are tri-salt compounds comprising a compound having two acidic functional groups and one basic functional groups (e.g. aspartate or glutamate) metformin and polyunsaturated fatty acids such as eicosapentaenoate or docosahexaenoate. The salts can be used in the treatment of diabetes diabetes with concomitant dyslipidemia (e.g. high triglycerides) and diabetes exacerbated cardiovascular complications such as cardiac arrhythmia cardiac ischemia myocardial infarction cardiomyopathy ...

The invention relates to novel Rauwolfia alkaloid derivatives of formula (I) combinations of Rauwolfia alkaloid derivatives and a mitochondrial inhibitor e.g. metformin and the use of Rauwolfia alkaloid derivatives in combination with mitochondrial inhibitor for the treatment of cancer and for achieving clinical immunosuppression. The invention also relates to a fluorescence-based method for predicting the sensitivity of a cancer cell towards a compound of formula (I).